In no area is there as much emphasis on anticounterfeiting than in the drug industry. Expect to see even more activity in this area now that the Food and Drug Administration’s February report, “Combating Counterfeit Drugs,” is out. Both prescription-only and over-the-counter (OTC) drugs will be affected.
“The Counterfeit Drug Task Force final report focuses on the prescription drug supply because that’s where we’ve seen the most counterfeiting occur,” says Ilisa Bernstein, senior science policy advisor at FDA. “The counterfeiters target higher-priced drugs and prescription drugs that cost much more than OTC drugs. However, that doesn’t mean that OTC drugs are not at risk. Consumers should be vigilant when buying OTCs as well.”
